Currently, there are 46.70M common shares owned by the public and among those 46.36M shares have been available to trade.
The company’s stock has a 5-day price change of -8.44% and -31.85% over the past three months. CLB shares are trading -37.32% year to date (YTD), with the 12-month market performance down to -42.38% lower. It has a 12-month low price of $10.14 and touched a high of $25.13 over the same period. CLB has an average intraday trading volume of 499.97K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.84%, -15.30%, and -36.23% respectively.
Institutional ownership of Core Laboratories Inc (NYSE: CLB) shares accounts for 109.35% of the company’s 46.70M shares outstanding.
It has a market capitalization of $508.68M and a beta (3y monthly) value of 1.43. The stock’s trailing 12-month PE ratio is 18.50, while the earnings-per-share (ttm) stands at $0.59. The company has a PEG of 5.52 and a Quick Ratio of 1.64 with the debt-to-equity ratio at 0.71. Price movements for the stock have been influenced by the stock’s volatility, which stands at 0.95% over the week and 3.14% over the month.
Earnings per share for the fiscal year are expected to decrease by -15.51%, and 16.42% over the next financial year. EPS should grow at an annualized rate of 3.35% over the next five years, compared to -20.53% over the past 5-year period.
Looking at the support for the CLB, a number of firms have released research notes about the stock. Citigroup stated their Neutral rating for the stock in a research note on March 12, 2025, with the firm’s price target at $15-$16. Citigroup coverage for the Core Laboratories Inc (CLB) stock in a research note released on June 30, 2023 offered a Sell rating with a price target of $21. Citigroup on their part issued Neutral rating on October 07, 2022.
